Other manufacturing industries
Rebirthel Co., Ltd.
Rebirthel Co., Ltd.
The vision of Rebirthel Co., Ltd. is to pioneer a new era for treating diseases through the transfusion of T cell preparations.
Rebirthel was established in 2019, following the world’s first successful regeneration of antigen-specific killer T cells from iPS cells by Professor Hiroshi Kawamoto of Kyoto University in 2013.
An estimated 20 million new cancer cases are diagnosed each year worldwide, and about 40% of them are not expected to reach remission. Rebirthel works to solve these unmet medical needs.
Using our patented technologies, we have developed a highly universal allogeneic T cell preparation, T cells regenerated from pluripotent stem cells that are capable of killing cancer cells, to provide a new treatment for advanced or recurrent cancers that are difficult to cure with standard therapies.
This allogeneic immune cell therapy is effective not only for cancer but also for immune-related diseases, including infections, autoimmune diseases, and allergies. The realization of this new therapy has led to the hope that diseases that have been considered difficult to treat can be completely cured.
Area of Interest
Site-visit
SDGs we are working on
Registered Keyword
Rebirthel was established in 2019, following the world’s first successful regeneration of antigen-specific killer T cells from iPS cells by Professor Hiroshi Kawamoto of Kyoto University in 2013.
An estimated 20 million new cancer cases are diagnosed each year worldwide, and about 40% of them are not expected to reach remission. Rebirthel works to solve these unmet medical needs.
Using our patented technologies, we have developed a highly universal allogeneic T cell preparation, T cells regenerated from pluripotent stem cells that are capable of killing cancer cells, to provide a new treatment for advanced or recurrent cancers that are difficult to cure with standard therapies.
This allogeneic immune cell therapy is effective not only for cancer but also for immune-related diseases, including infections, autoimmune diseases, and allergies. The realization of this new therapy has led to the hope that diseases that have been considered difficult to treat can be completely cured.
Area of Interest
Site-visit
Not allowed
SDGs we are working on
3.Good health and well-being
Registered Keyword
Our allogeneic immune cell therapy has the potential for application to solid tumors, as well as hematological cancer, by introducing T cell receptor genes that specifically recognize antigens into pluripotent stem cells to regenerate highly cytotoxic-active killer T cells with tumor invasion capabilities. The regenerated cells can be cryopreserved to provide off-the-shelf just-in-time treatment. The underlying technology is patented all over the world.